The protective effects of levosimendan on ischemia/reperfusion injury and apoptosis

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 1, 2011, Pages 20-26

  Scheiermann, Patrick ^a,b   Beiras Fernandez, Andres ^a   Mutlak, Haitham ^c   Weis, Florian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Pharmazentrum/ZAFES ^*  (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Calcium sensitizer; Caspase 3; Patents; Protection; TUNEL staining

Indexed keywords

DOBUTAMINE; FAS LIGAND; LEVOSIMENDAN; PLACEBO; TROPONIN C;

APOPTOSIS; ARTICLE; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART ARREST; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY;

ANIMALS; APOPTOSIS; CARDIOVASCULAR AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; HYDRAZONES; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PATENTS AS TOPIC; POTASSIUM CHANNELS; PYRIDAZINES; TREATMENT OUTCOME;

EID: 79551665968     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489011794578482     Document Type: Article

References (101)

1. Bäckström, R.H., Granvik, P., Haikala, R., Pelttari, S., Saukko, E., Yrjölä, R. Pharmaceutical solutions of levosimendan. US6730673 (2004).
2. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19: 660-668.
3. Perrone SV, Kaplinsky EJ. Calcium sensitizer agents: A new class of inotropic agents in the treatment of decompensated heart failure. Int J Cardiol 2005; 103: 248-255.
4. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin C. Mol Cell Biochem 2004; 266: 87-107.
5. Endoh M. Mechanism of action of Ca2+ sensitizers--update 2001. Cardiovasc Drugs Ther 2001; 15: 397-403.
6. Papp Z, Csapo K, Pollesello P, Haikala H, Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005; 23: 71-98.
7. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27: 1859-1866.
8. De Witt BJ, Ibrahim IN, Bayer E, Fields AM, Richards TA, Banister RE, et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 2002; 94:1427-1433.
9. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005; 111: 1504-1509.
10. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102: 2222-2227.
11. Rehberg S, Ertmer C, Van Aken H, Lange M, Broking K, Morelli A, et al. Role of Levosimendan in intensive care treatment of myocardial insufficiency. Anaesthesist 2007; 56: 30-43.
12. Kleemann, R.I., Troetschel, C., Vollmar, A. Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure. US20100273807 (2010).
13. Daemmgen, J.O., Joens, O., Kleemann, R., Troetschel, C., Vollmar, A. Use of PDE III Inhibitors for the treatment of asymptomatic (occult) heart failure. US20100035889 (2010).
14. Mathew L, Katz SD. Calcium sensitising agents in heart failure. Drugs Aging 1998; 12: 191-204.
15. Holubarsch C. New inotropic concepts: Rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology 1997; 88 (Suppl 2): 12-20.
16. Holubarsch C, Ludemann J, Wiessner S, Ruf T, Schulte-Baukloh H, Schmidt-Schweda S, et al. Shortening versus isometric contractions in isolated human failing and non-failing left ventricular myocardium: Dependency of external work and forceon muscle length, heart rate and inotropic stimulation. Cardiovasc Res 1998; 37: 46-57.
17. Ng TM. Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy 2004; 24: 1366-1384.
18. Ishiki R, Ishihara T, Izawa H, Nagata K, Hirai M, Yokota M. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure. J Cardiovasc Pharmacol 2000; 35: 897-905.
19. Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J, et al. Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223-231.
20. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891.
21. Poeder, P., Haikala, H. Composite treatment for heart failure treatment. JP2010065060 (2010).
22. Okada, Y., Uramoto, H. Novel method of protecting ischemic cardiopathy. EP1839675 (2007).
23. Monassier JP. Reperfusion injury in acute myocardial infarction. From bench to cath lab. Part I: Basic considerations. Arch Cardiovasc Dis 2008; 101: 491-500.
24. Monassier JP. Reperfusion injury in acute myocardial infarction: From bench to cath lab. Part II: Clinical issues and therapeutic options. Arch Cardiovasc Dis 2008; 101: 565-575.
25. Scheiermann C, Colom B, Meda P, Patel NS, Voisin MB, Marrelli A, et al. Junctional adhesion molecule-C mediates leukocyte infiltration in response to ischemia reperfusion injury. Arterioscler Thromb Vasc Biol 2009; 29: 1509-1515.
26. Kanoria S, Jalan R, Seifalian AM, Williams R, Davidson BR. Protocols and mechanisms for remote ischemic preconditioning: A novel method for reducing ischemia reperfusion injury. Transplantation 2007; 84: 445-458.
27. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004; 68: 807-812.
28. + channel in rat arterial myocytes. Eur J Pharmacol 1997; 333: 249-259.
29. + channel in rat ventricular cells. J Pharmacol Exp Ther 1997; 283: 375-383.
30. + channels and myocardial preconditioning. Circ Res 1999; 84: 973-979.
31. Dobson, G.P. Transplants. US20100119554 (2010).
32. Dobson, G.P. Trauma therapy. US20090324748 (2009).
33. Meier P, Finch A, Evan G. Apoptosis in development. Nature 2000; 407: 796-801.
34. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999; 68: 383-424.
35. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
36. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922-2933.
37. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003; 39: 615-647.
38. Patterson SD, Spahr CS, Daugas E, Susin SA, Irinopoulou T, Koehler C, et al. Mass spectrometric identification of proteins released from mitochondria undergoing permeability transition. Cell Death Differ 2000; 7: 137-144.
39. Scheiermann P, Ahluwalia D, Hoegl S, Dolfen A, Revermann M, Zwissler B, et al. Effects of intravenous and inhaled levosimendan in severe rodent sepsis. Intensive Care Med 2009; 35: 1412-1419.
40. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
41. Loop T, Dovi-Akue D, Frick M, Roesslein M, Egger L, Humar M, et al. Volatile anesthetics induce caspase-dependent, mitochondriamediated apoptosis in human T lymphocytes in vitro. Anesthesiology 2005; 102: 1147-1147.
42. Maytin M, Colucci WS. Cardioprotection: A new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005; 96: 26G-31G.
43. Kankaanranta H, Zhang X, Tumelius R, Ruotsalainen M, Haikala H, Nissinen E, et al. Antieosinophilic activity of simendans. J Pharmacol Exp Ther 2007; 323: 31-38.
44. Sallinen, J.T., Kuoppamäki, M., Levijoki, J. Combination treatment. US20100249103 (2010).
45. Levijoki, J. A combination comprising levosimendan and a calcium source for the treatment of heart failure. EP1363636 (2010).
46. Westerholm, F., Levijoki, J., Korpivaara, M., Leppänen, M. Levosimendan for use in treating chronic valvular disease. US20100286150 (2010).
47. Kurkela, K., Marvola, M., Larma, I., Virtanen, R., Karlsson, M. Transmucosal formulations of levosimendan. US6399610 (2002).
48. Bäckman, M., Larma, I., Antila, S., Lehtonen, L. Oral compositions of levosimendan. US6355269 (2002).
49. Larma, I., Bäckman, M., Antila, S., Lehtonen, L. Controlled release peroral compositions of levosimendan. US7045147 (2006).
50. Urtti, A., Hirvonen, J., Lehtonen, L., Antila, S. Transdermal compositions containing levosimendan. US6183771 (2001).
51. Larma, I., Baeckman, M., Antila, S., Lehtonen, L. Controlled release peroral composition of levosimendan. JP2010083900 (2010).
52. Edelman, E., Lovich, M. Devices and systems for local delivery of inotropic agents to the epicardium. WO2010027851 (2010).
53. Lovich, M., Edelman, E. Devices and systems for local delivery of inotropic agents to the epicardium. US20100057039 (2010).
54. Rump AF, Acar D, Rosen R, Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 1994; 74: 244-248.
55. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997; 85: 23-29.
56. Kristof E, Szigeti G, Papp Z, Bodi A, Ball NA, Walsh RA, et al. The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts. Basic Res Cardiol 1999; 94: 223-230.
57. du Toit EF, Muller CA, McCarthy J, Opie LH. Levosimendan: Effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999; 290: 505-514.
58. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000; 90: 5-11.
59. du Toit E, Hofmann D, McCarthy J, Pineda C. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart 2001; 86: 81-87.
60. Eriksson O, Pollesello P, Haikala H. Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. J Cardiovasc Pharmacol 2004; 44: 316-321.
61. Busk M, Maeng M, Kristensen J, Berg JS, Mortensen UM, Nielsen TT, et al. Effects of levosimendan on myocardial infarct size and hemodynamics in a closed-chest porcine ischemia-reperfusion model. Cardiovasc Drugs Ther 2006; 20: 335-342.
62. Lepran I, Pollesello P, Vajda S, Varro A, Papp JG. Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model. J Cardiovasc Pharmacol 2006; 48: 148-152.
63. Papp JG, Pollesello P, Varro AF, Vegh AS. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusioninduced arrhythmias in dogs. J Cardiovasc Pharmacol Ther 2006; 11: 129-135.
64. Missant C, Rex S, Segers P, Wouters PF. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med 2007; 35: 707-715.
65. Meyer K, Schipke JD, Klocke RC, Gams E, Korbmacher B. Inotropic, vasodilating and preconditioning actions of levosimendan in the heart. Thorac Cardiovasc Surg 2008; 56: 379-385
66. 2+ sensitizer superior to catecholamine during myocardial stunning? Eur J Cardiothorac Surg 2008; 34: 326-331.
67. du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A. A role for the RISK pathway and K(ATP) channels in pre- and postconditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol 2008; 154: 41-50.
68. Yapici D, Altunkan Z, Ozeren M, Bilgin E, Balli E, Tamer L, et al. Effects of levosimendan on myocardial ischaemia-reperfusion injury. Eur J Anaesthesiol 2008; 25: 8-14.
69. Das B, Sarkar C. Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model. Vascul Pharmacol 2007; 47: 248-256.
70. Pöder, P., Haikala, H. Combination therapy for the treatment of heart failure. US6949548 (2005).
71. Haikala, H., Hyttilä-hopponen, M., Nissinen, E., Ruotsalainen, M., Pippuri, A., Lönnberg, K. Anti-inflammatory agents. US6878702 (2005).
72. Oldner, A., Wanecek, M., Weitzberg, E., Rudehill, A. Method for treating septic shock. US7485642 (2009).
73. Hein M, Roehl AB, Baumert JH, Scherer K, Steendijk P, Rossaint R. Anti-ischemic effects of inotropic agents in experimental right ventricular infarction. Acta Anaesthesiol Scand 2009; 53: 941-948.
74. Metzsch C, Linner R, Steen S, Liao Q, Algotsson L. Levosimendan cardioprotection in acutely beta-1 adrenergic receptor blocked open chest pigs. Acta Anaesthesiol Scand 2010; 54: 103-10.
75. Lafci B, Yasa H, Ilhan G, Ortac R, Yilik L, Kestelli M, et al. Protection of the spinal cord from ischemia: Comparative effects of levosimendan and iloprost. Eur Surg Res 2008; 41:1-7.
76. Katircioglu SF, Seren M, Parlar AI, Turan NN, Manavbasi Y, Aydog G, et al. Levosimendan effect on spinal cord ischemiareperfusion injury following aortic clamping. J Card Surg 2008; 23: 44-48.
77. Yasa H, Yakut N, Emrecan B, Ergunes K, Ortac R, Karahan N, et al. Protective effects of levosimendan and iloprost on lung injury induced by limb ischemia-reperfusion: A rabbit model. J Surg Res 2008; 147: 138-142.
78. Yakut N, Yasa H, Bahriye Lafci B, Ortac R, Tulukoglu E, et al. The influence of levosimendan and iloprost on renal ischemiareperfusion: An experimental study. Interact Cardiovasc Thorac Surg 2008; 7: 235-239.
79. Kivikko, M., Haikala, H. A method for treating renal failure. EP1581227 (2007).
80. Ozturk T, Gok S, Nese N. Levosimendan attenuates reperfusion injury in an isolated perfused rat heart model. J Cardiothorac Vasc Anesth 2010; 24: 624-628.
81. Grossini E, Caimmi PP, Platini F, Molinari C, Uberti F, Cattaneo M, et al. Modulation of programmed forms of cell death by intracoronary levosimendan during regional myocardial ischemia in anesthetized pigs. Cardiovasc Drugs Ther 2010; 24: 5-15.
82. Louhelainen M, Vahtola E, Forsten H, Merasto S, Kyto V, Finckenberg P, et al. Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats. J Hypertens 2009; 27: 2094-2107.
83. Lochner A, Colesky F, Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium. Cardiovasc Drugs Ther 2000; 14: 271-281.
84. Koksal C, Suzer O, Bozkurt AK, Koseoglu S. Comparison of enoximone, amrinone, or levosimendan enriched St. Thomas' hospital cardioplegic solutions used for myocardial preservation in isolated guinea pig hearts. Acta Med (Hradec Kralove) 2002; 45: 93-97.
85. Huang L, Weil MH, Tang W, Sun S, Wang J. Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction. Crit Care Med 2005; 33: 487-491.
86. Wang J, Weil MH, Tang W, Sun S, Huang L. Levosimendan improves postresuscitation myocardial dysfunction after betaadrenergic blockade. J Lab Clin Med 2005; 146: 179-183.
87. Huang L, Weil MH, Sun S, Cammarata G, Cao L, Tang W. Levosimendan improves postresuscitation outcomes in a rat model of CPR. J Lab Clin Med 2005; 146: 256-261.
88. Koudouna E, Xanthos T, Bassiakou E, Goulas S, Lelovas P, Papadimitriou D, et al. Levosimendan improves the initial outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest. Acta Anaesthesiol Scand 2007; 51: 1123-1129.
89. Landoni G, Mizzi A, Biondi-Zoccai G, Bruno G, Bignami E, Corno L, et al. Reducing mortality in cardiac surgery with levosimendan: A meta-analysis of randomized controlled trials. J ardiothorac Vasc Anesth 2010; 24: 51-57.
90. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebocontrolled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-1432.
91. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43: 2177-2182.
92. Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting-a pilot study. Br J Anaesth 2006; 96: 694-700.
93. Lehtonen, L., Papp, J., Szecsi, J. Method for the treatment or prevention of coronary graft vasospasm. US6593329 (2003).
94. De Luca L, Sardella G, Proietti P, Battagliese A, Benedetti G, Di Roma A, et al. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: A Doppler echocardiographic study. J Am Soc Echocardiogr 2006; 19: 172-177.
95. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, et al. Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004; 93: 1309-1312.
96. Trikas A, Antoniades C, Latsios G, Vasiliadou K, Karamitros I, Tousoulis D, et al. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 2006; 8: 804-809.
97. Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98: 102-106.
98. Krumnikl JJ, Toller WG, Prenner G, Metzler H. Beneficial outcome after prostaglandin-induced post-partum cardiac arrest using levosimendan and extracorporeal membrane oxygenation. Acta Anaesthesiol Scand 2006; 50: 768-770.
99. Papadopoulos G, Baikoussis NG, Tzimas P, Siminelakis SN, Karanikolas M. Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction. J Cardiothorac Surg 2010; 5: 9.
100. Koumallos N, Antoniades C, Tousoulis D, Shirodaria C, Stefanadis C. Levosimendan: A novel agent in heart failure. Recent Pat Cardiovasc Drug Discov 2006; 1: 185-191.
101. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Abreu-Gonzalez P. New pharmacologic options in the treatment of acute coronary syndromes and myocardial ischemia-reperfusion injury: Potential role of levosimendan. Minerva Cardioangiol 2007; 55: 625-635.